Sheep milk could be an inexpensive source of therapeutic polyclonal SARS-CoV-2 neutralizing antibodies biorxivpreprint waikato SARSCoV2 COVID19 Milk SheepsMilk
By Neha MathurDec 15 2022Reviewed by Aimee Molineux In a recent study posted to the bioRxiv* preprint server, researchers used sheep, a ruminant mammal, to obtain polyclonal immunoglobulins against severe acute respiratory syndrome coronavirus 2 .
Recently, Kangro et al. immunized expectant cows with the SARS-CoV-2 RBD and used the antibodies in their colostrum for nasal application, which protected against infection for nearly four hours in a small-scale clinical study. These antibodies closely resembled pathogen-specific nAbs induced by vaccination in humans. However, it remains challenging to induce high nAb titers in ruminant colostrum.
Next, the team synthesized antigen plasmid constructs to design three recombinant antigens, S IgG2 Fc, RBD IgG2 Fc, and RBD GM-CSF, from which they purified proteins using an automated liquid chromatography system. Sodium dodecyl-sulfate polyacrylamide gel electrophoresis confirmed all antigens were over 80% pure.
Study findings The study results showed that the vaccination of sheep with fusion immunogens promoted substantially higher levels of antigen-specific polyclonal nAbs compared to full-length S and native RBD antigens. In vitro assessments showed that these antibodies had higher levels of nAbs that inhibit binding between the RBD and human angiotensin-converting enzyme 2 receptors. ELISA screening revealed that the RBD IgG2a Fc antigen design increased anti-RBD titer by 3.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
What is the relation between COVID-19 vaccination and new POTS-related diagnoses?What is the relation between COVID-19 vaccination and new POTS-related diagnoses? NatureCVR CedarsSinai BrighamWomens COVID19 coronavirus covid vaccination vaccine diagnosis cardiac cardiology coronavirus
Read more »
Bioinformatics approach for the design of siRNAs against SARS-CoV-2Bioinformatics approach for the design of siRNAs against SARS-CoV-2 biorxivpreprint umontpellier RNA siRNA SARSCoV2 COVID19 coronavirus covid bioinformatics
Read more »
Inhibition of glycogen synthase kinase-3-beta (GSK3β) blocks nucleocapsid phosphorylation and SARS-CoV-2 replication - Molecular BiomedicineGSK3β has been proposed to have an essential role in Coronaviridae infections. Screening of a targeted library of GSK3β inhibitors against both SARS-CoV-2 and HCoV-229E to identify broad-spectrum anti-Coronaviridae inhibitors resulted in the identification of a high proportion of active compounds with low toxicity to host cells. A selected lead compound, T-1686568, showed low micromolar, dose-dependent activity against SARS-CoV-2 and HCoV-229E. T-1686568 showed efficacy in viral-infected cultured cells and primary 2D organoids. T-1686568 also inhibited SARS-CoV-2 variants of concern Delta and Omicron. Importantly, while inhibition by T-1686568 resulted in the overall reduction of viral load and protein translation, GSK3β inhibition resulted in cellular accumulation of the nucleocapsid protein relative to the spike protein. Following identification of potential phosphorylation sites of Coronaviridae nucleocapsid, protein kinase substrate profiling assays combined with Western blotting analysis of nine host kinases showed that the SARS-CoV-2 nucleocapsid could be phosphorylated by GSK3β and PKCa. GSK3β phosphorylated SARS-CoV-2 nucleocapsid on the S180/S184, S190/S194 and T198 phospho-sites, following previous priming in the adjacent S188, T198 and S206, respectively. Such inhibition presents a compelling target for broad-spectrum anti-Coronaviridae compound development, and underlies the mechanism of action of GSK3β host-directed therapy against this class of obligate intracellular pathogens.
Read more »
Research reveals that a viral toxin may contribute to the severity of COVID-19Research reveals that a viral toxin may contribute to the severity of COVID-19 Coronavirus Disease COVID Protein SARSCoV2 SpikeProtein Vascular NatureComms
Read more »
Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occursStudy indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs CIDJournal NIAIDNews FredNatLab SARSCoV2 infection vaccine vaccination mucosal
Read more »
Polymorphisms in human immunoglobulin heavy chain genes can influence the function of SARS-CoV-2 neutralizing antibodiesPolymorphisms in human immunoglobulin heavy chain genes can influence the function of SARS-CoV-2 neutralizing antibodies ImmunityCP karolinskainst polymorphism gene genetics SARSCoV2 coronavirus covid antibody antibodies
Read more »